entity,start_date,end_date,context,AARSRAPPORT_html,AARSRAPPORT_pdf,AARSRAPPORT_xml,AddressOfAuditorCountry,AddressOfAuditorDistrictName,AddressOfAuditorPostCodeIdentifier,AddressOfAuditorStreetBuildingIdentifier,AddressOfAuditorStreetName,AddressOfReportingEntityDistrictName,AddressOfReportingEntityPostCodeIdentifier,AddressOfReportingEntityStreetBuildingIdentifier,AddressOfReportingEntityStreetName,AddressOfSubmittingEnterprisePostcodeAndTown,AddressOfSubmittingEnterpriseStreetAndNumber,AddresseeOfAuditorsReportOnAuditedFinancialStatements,ClassOfReportingEntity,ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement,ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults,DateOfApprovalOfAnnualReport,DateOfApprovalOfReport,DateOfFoundationOfReportingEntity,DateOfGeneralMeeting,DescriptionOfAnyUncertaintyConnectedWithRecognitionOrMeasurement,DescriptionOfAnyUnusualMattersAffectingRecognitionOrMeasurement,DescriptionOfMethodsOfAmortisationOfNoncurrentAssets,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfAdministrativeExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeAssets,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherOperatingIncomeAndExpenses,DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod,DescriptionOfSpecificRisksInAdditionToCommonlyOccurringHazardsInIndustry,DisclosureOfDepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss,DisclosureOfOtherOperatingExpenses,DisclosureOfProvisionsForDeferredTax,DisclosureOfTaxExpenseOnOrdinaryActivities,Equity,ExplanationOfNotDisclosingCashFlowsStatements,ExplanationOfOtherMethodsOfRecognitionAndMeasurementBasisForAssetsInPreviousPeriod,FaxNumberOfReportingEntity,HomepageOfReportingEntity,IdentificationNumberCvrOfReportingEntity,IdentificationNumberCvrOfSubmittingEnterprise,IdentificationOfApprovedAnnualReport,IdentificationOfAuditedFinancialStatements,IncreaseDecreaseOfIntangibleAssetsThroughTransfers,InformationOnRemunerationOfManagementCategoriesAndSpecialIncentiveProgrammes,InformationOnReportingClassOfEntity,InformationOnSegments,InformationOnTypeOfSubmittedReport,ManagementsStatementAboutManagementsReview,NameAndSurnameOfChairmanOfGeneralMeeting,NameAndSurnameOfMemberOfExecutiveBoard,NameOfReportingEntity,NameOfSubmittingEnterprise,OpinionOnAuditedFinancialStatements,PlaceOfSignatureOfStatement,RecommendationForApprovalOfAnnualReportByGeneralMeeting,RegisteredOfficeOfReportingEntity,ReportingPeriodEndDate,ReportingPeriodStartDate,RetrospectiveInformationOnContributedCapital,SignatureOfAuditorsDate,SignatureOfAuditorsPlace,StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements,StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements,TelephoneNumberOfAuditor,TelephoneNumberOfReportingEntity,TitleOfMemberOfSupervisoryBoard,TransferImpairmentLossesAndAmortisationOfIntangibleAssets,TypeOfAuditorAssistance,_id,_index,_score,cvrNummer,indlaesningsId,indlaesningsTidspunkt,offentliggoerelsesTidspunkt,offentliggoerelsestype,omgoerelse,regNummer,regnskabsperiode_slutDato,regnskabsperiode_startDato,sagsNummer,sidstOpdateret,ProfitLoss,FeesForAuditorsPerformingStatutoryAudit,AdjustmentsForCurrentTaxOfPriorPeriod,AdjustmentsForDeferredTax,AdministrativeExpenses,AmortisationOfIntangibleAssets,AverageNumberOfEmployees,CostOfProduction,CurrentTaxExpense,DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss,DepreciationOfPropertyPlantAndEquipment,EmployeeBenefitsExpense,EquityRatio,ExchangeRateAdjustmentsOtherFinanceExpenses,ExchangeRateLoss,ExchangeRateProfit,GrossMargin,InterestExpenseAssignedToGroupEnterprises,InterestIncomeFromGroupEnterprises,InterestSubsidyForTaxOnAccount,InvestmentInPropertyPlantAndEquipment,OperatingMargin,OtherAdjustmentsOfFinanceExpenses,OtherAdjustmentsOfFinanceIncome,OtherFinanceExpenses,OtherFinanceIncome,OtherOperatingExpenses,OtherOperatingIncome,PostemploymentBenefitExpense,ProfitLossFromOrdinaryActivitiesBeforeTax,ResultsFromNetFinancials,ReturnOnCapitalEmployed,ReturnOnEquity,Revenue,SocialSecurityContributions,TaxExpenseOnOrdinaryActivities,WagesAndSalaries,NominalValueOfIssuedShares,AcquiredIntangibleAssets,Assets,CashAndCashEquivalents,ContributedCapital,CurrentAssets,FixturesFittingsToolsAndEquipment,IntangibleAssets,LandAndBuildings,LeaseholdImprovements,LiabilitiesAndEquity,LiabilitiesOtherThanProvisions,NoncurrentAssets,OtherAccruedExpenses,OtherShorttermPayables,OtherShorttermReceivables,PropertyPlantAndEquipment,PropertyPlantAndEquipmentInProgress,Provisions,ProvisionsForDeferredTax,RetainedEarnings,ShorttermLiabilitiesOtherThanProvisions,ShorttermPayablesToGroupEnterprises,ShorttermReceivables,ShorttermReceivablesFromGroupEnterprises,ShorttermTaxPayables,ShorttermTaxReceivables,ShorttermTradePayables,AccumulatedImpairmentLossesAndAmortisationOfIntangibleAssets,IntangibleAssetsGross,AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment,PropertyPlantAndEquipmentGross,DescriptionOfAuditor,NameAndSurnameOfAuditor,AdditionsToPropertyPlantAndEquipment,DisposalsOfPropertyPlantAndEquipment,IncreaseDecreaseOfPropertyPlantAndEquipmentThroughTransfers,ReversalsOfImpairmentLossesAndDepreciationOfDisposedPropertyPlantAndEquipment,TransferImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment,NameAndSurnameOfMemberOfSupervisoryBoard,ProfitLossFromOrdinaryOperatingActivities,DescriptionOfClassOfIssuedShares
26060702,2014-01-01,2014-01-01,c309,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",390000.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-01-01,2014-01-01,c354,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",3471696000.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-01-01,2014-12-31,c195,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,141254000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-01-01,2014-12-31,c2014,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,1035000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-01-01,2014-12-31,c355,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,141254000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-01-01,2014-12-31,c433,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,141254000.0,,-2159000.0,43684000.0,95797000.0,2692000.0,552000.0,897162000.0,0.0,192451000.0,189759000.0,475132000.0,88.9,0.0,0.0,0.0,22.2,0.0,1000.0,0.0,417653.0,13.9,1162000.0,23664000.0,1162000.0,23665000.0,515000.0,0.0,32530000.0,182779000.0,22503.0,4.1,4.0,1153750000.0,5490000.0,41525000.0,437112000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-12-31,2014-12-31,c1294,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,385000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-12-31,2014-12-31,c5,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",3613340000.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12201000.0,4066767000.0,215917000.0,390000.0,384357000.0,1375529000.0,12201000.0,1907933000.0,5788000.0,4066767000.0,345578000.0,3682410000.0,113020000.0,113020000.0,25223000.0,3670209000.0,380959000.0,107849000.0,107849000.0,3612950000.0,345578000.0,21133000.0,168440000.0,143217000.0,0.0,0.0,211425000.0,,,,,,,,,,,,,,
26060702,2015-01-01,2015-01-01,c136,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,19046000.0,31246000.0,,,,,,,,,,,,
26060702,2015-01-01,2015-01-01,c217,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,436077000.0,2344010000.0,,,,,,,,,,
26060702,2015-01-01,2015-01-01,c235,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,358331000.0,1733860000.0,,,,,,,,,,
26060702,2015-01-01,2015-01-01,c242,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3717000.0,9506000.0,,,,,,,,,,
26060702,2015-01-01,2015-01-01,c246,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,380959000.0,,,,,,,,,,
26060702,2015-01-01,2015-01-01,c312,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",390000.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2015-01-01,2015-01-01,c351,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",3612950000.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2015-01-01,2015-12-31,c1,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,-124280000.0,,-80771000.0,21905000.0,92157000.0,3289000.0,608000.0,993992000.0,-3334000.0,262616000.0,259327000.0,498320000.0,79.5,2673000.0,22795000.0,10294000.0,14.3,781000.0,0.0,53209000.0,756407.0,-19.3,142000.0,36000.0,26391000.0,63539000.0,384956000.0,87314000.0,37296000.0,-186480000.0,37148.0,-5.3,-3.5,1160163000.0,6024000.0,-62200000.0,455000000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2015-01-01,2015-12-31,c105,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,state authorised public accountant,Rikke Lund-KÃ¼hl,,,,,,,,
26060702,2015-01-01,2015-12-31,c106,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,1036000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,state authorised public accountant,Torben Jensen,,,,,,,,
26060702,2015-01-01,2015-12-31,c137,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,4617000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2015-01-01,2015-12-31,c194,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,-124280000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2015-01-01,2015-12-31,c222,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,113629000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,73595000.0,0.0,-791000.0,,,
26060702,2015-01-01,2015-12-31,c236,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,141660000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,9340000.0,75156000.0,9337000.0,1053000.0,,,
26060702,2015-01-01,2015-12-31,c243,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,2711000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,,,
26060702,2015-01-01,2015-12-31,c247,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,756407000.0,0.0,-150073000.0,0.0,0.0,,,
26060702,2015-01-01,2015-12-31,c33,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Inga Birgitte Thygesen,,
26060702,2015-01-01,2015-12-31,c352,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,-124280000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2015-01-01,2015-12-31,c435,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,102686.0,,,,,,483.0,,,,,,91.8,,,,20.3,,,,165635.0,12.9,,,,,,,,,-6889.0,3.6,2.9,1054130.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,135606.0,
26060702,2015-01-01,2015-12-31,c438,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,49803.0,,,,,,375.0,,,,,,93.3,,,,22.1,,,,193567.0,10.0,,,,,,,,,620.0,1.8,1.4,660824.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,65857.0,
26060702,2015-01-01,2015-12-31,c441,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,41103.0,,,,,,200.0,,,,,,96.5,,,,22.4,,,,144528.0,12.1,,,,,,,,,6226.0,1.2,1.2,377812.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,45576.0,
26060702,2015-01-01,2015-12-31,c49,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Allan Frank Fischer Petersen,,
26060702,2015-01-01,2015-12-31,c50,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Marianne Leth,,
26060702,2015-01-01,2015-12-31,c76,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2015-12-31,2015-12-31,c138,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8643000.0,,,,,,,,,,,,,,,,,,,,,23925000.0,32568000.0,,,,,,,,,,,,
26060702,2015-12-31,2015-12-31,c223,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1867108000.0,,,,,,,,,,,,,,550497000.0,2417605000.0,,,,,,,,,,
26060702,2015-12-31,2015-12-31,c237,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1310075000.0,,,,,,,,,,,,,,489601000.0,1799676000.0,,,,,,,,,,
26060702,2015-12-31,2015-12-31,c244,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3078000.0,,,,,,,,,,,,,,6428000.0,9506000.0,,,,,,,,,,
26060702,2015-12-31,2015-12-31,c248,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,987293000.0,,,,,,,,,,,,,,0.0,987293000.0,,,,,,,,,,
26060702,2015-12-31,2015-12-31,c314,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",390000.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2015-12-31,2015-12-31,c353,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",3488670000.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2015-12-31,2015-12-31,c437,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",3472087.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3784036.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2015-12-31,2015-12-31,c440,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",3512401.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3763371.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2015-12-31,2015-12-31,c443,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",3462587.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3586870.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2015-12-31,2015-12-31,c7,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",3489060000.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8645000.0,4391087000.0,11092000.0,390000.0,214888000.0,1310075000.0,8645000.0,1867108000.0,3078000.0,4391087000.0,772273000.0,4176199000.0,128581000.0,128581000.0,71912000.0,4167554000.0,987293000.0,129754000.0,129754000.0,3488670000.0,772273000.0,479515000.0,203796000.0,35646000.0,15467000.0,96238000.0,148710000.0,,,,,,,,,,,,,,
26060702,2015-12-31,2015-12-31,c72,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzc0LzQwLzA1L2IyL2M4MmItNDQzMi05OTg5LWEyYTMwNTQ4NTMyMg.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzcyLzQ5L2EyLzc1LzRlZjctNGRkOS1hMzEwLTRkYmEzNWY5MGNmNQ.xml,Danmark,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,1.0,Biogen AllÃ©,"Postboks 250, 2000 Frederiksberg",Osvald Helmuths Vej 4,To the shareholders of Biogen (Denmark) Manufacturing ApS,"Regnskabsklasse C, stor virksomhed",The annual report is prepared in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.",2016-05-24,2016-05-24,2001-06-01,2016-05-24,None.,None.,"Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.","Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.",Cash and cash equivalents comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.,Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.,"Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance-payment-of-tax scheme, etc.","Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.","Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.","For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.","Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 248,144 and Administrative expenses with t.kr. 14,472.","Other operating expenses include tax adjustment and losses on the sale of property, plant and equipment, including other operating equipment.","The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.","Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.",,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.",The accounting policies applied by the company are consistent with those of last year.,77416070.0,www.biogen.dk,26060702.0,30700228.0,The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January - 31 December 2015.,"We have audited the Financial Statements of Biogen (Denmark) Manufacturing ApS for the financial year 1 January â 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.",1322000.0,"By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.",The annual report of Biogen (Denmark) Manufacturing ApS for 2015 has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.,Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.,Ãrsrapport,"Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.",Muna Yahaya,Marianne Leth,Biogen (Denmark) Manufacturing ApS,Ernst & Young Godkendt Revisionspartnerselskab,"In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.","Copenhagen,",We recommend the adoption of the annual report at the annual general meeting.,HillerÃ¸d,2015-12-31,2015-01-01,The Company's share capital  has remained DKK 390 thousand over the past 5 years.,2016-05-24,"Copenhagen,","Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.","We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Managementâs Review is consistent with the Financial Statements.",+45 39 45 39 45,77416000.0,Chairman,262000.0,RevisionspÃ¥tegning,urn:ofk:oid:22440239,indberetninger-20180424,2.5097437,26060702.0,,2018-03-29T02:49:51.437Z,2016-05-25T12:51:38.592Z,regnskab,0.0,,2015-12-31,2015-01-01,X16-AW-74-RT,2016-05-25T12:51:38.788Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,385000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,A
